- Home
- SDSTW vs CMMB Comparison
SDSTW vs CMMB Comparison
Compare SDSTW & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SDSTW | CMMB |
|---|---|---|
| Founded | N/A | 2004 |
| Country | United States | Israel |
| Employees | 8 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.9M | 11.2M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | SDSTW | CMMB |
|---|---|---|
| Price | $0.16 | $1.70 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | 7.0K | ★ 43.1K |
| Earning Date | 03-26-2025 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 101.67 |
| EPS | N/A | ★ 0.04 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $42.50 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.02 | $0.87 |
| 52 Week High | $0.30 | $3.86 |
Technical Indicators
Market Signals| Indicator | SDSTW | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 41.66 | 51.31 |
| Support Level | $0.10 | $1.44 |
| Resistance Level | $0.22 | $1.86 |
| Average True Range (ATR) | 0.03 | 0.13 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 22.40 | 62.26 |
Price Performance
Historical ComparisonAbout SDSTW Stardust Power Inc. Warrant
Stardust Power Inc is developing a lithium refinery at its Facility in Muskogee, Oklahoma, with planned capacity of producing up to 50,000 metric tons per annum of BGLC once fully operational. The company will source lithium brine feedstock from various suppliers and may make investments upstream to secure additional feedstock. The Company seeks to sell its products to electric vehicle (EV) manufacturers as the primary market, with potential applications in other areas such as battery manufacturers, the U.S. military, and original equipment manufacturers (OEMs).
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.